Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis.

Nooraldin MerzaYusuf NawrasOmar SaabDushyant Singh DahiyaZohaib AhmedMeghana RanabothuSafa BoujemaaMona HassanAbdallah KobeissyKirthi Lilley

Published in: Gastroenterology research (2023)

ADA and VDZ are effective and safe in CD and UC patients. However, RCTs of a larger number of patients are still required for better assessing the safety profile of ADA and VDZ.

Keyphrases

end stage renal disease
ulcerative colitis
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
rheumatoid arthritis
early onset
patient reported
disease activity